Editorial: 2008 British guidelines on the management of interstitial lung diseases What are the key new messages for clinical practice?

Polskie Archiwum Medycyny Wewnetrznej

Volumn 119, Issue 3, 2009, Pages 112-114

  Branley, Howard M ^a   Lake, Fiona R ^b  

^a WHITTINGTON HOSPITAL   (United Kingdom)

^b Thoracic Society of Australia   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; ILOPROST; IMMUNOSUPPRESSIVE AGENT; OPIATE; PLACEBO; PREDNISOLONE; PREDNISONE; STEROID;

ACUTE RESPIRATORY FAILURE; ALLERGIC PNEUMONITIS; ARTIFICIAL VENTILATION; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DRUG MEGADOSE; EDITORIAL; FIBROSING ALVEOLITIS; HEART FAILURE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INTERSTITIAL LUNG DISEASE; KIDNEY CRISIS; KIDNEY DISEASE; LOW DRUG DOSE; LUNG BIOPSY; LUNG FUNCTION; LUNG LAVAGE; MONOTHERAPY; NEOPLASM; OXYGEN THERAPY; PRACTICE GUIDELINE; PULMONARY REHABILITATION; TREATMENT OUTCOME; TREATMENT PLANNING; VASOSPASM; BIOPSY; LUNG; PATHOLOGY;

ADRENAL CORTEX HORMONES; BIOPSY; HUMANS; LUNG; LUNG DISEASES, INTERSTITIAL; PRACTICE GUIDELINES AS TOPIC;

EID: 64149126491     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (25)

1. Wells AU, Hirani N. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax. 2008; 63 (Suppl 5): 1-58.
2. Turner-Warwick M, Burrows B, Johnson A. Cryptogenic fibrosing alveolitis: Clinical features and there influence on survival. Thorax. 1980; 35: 171-180.
3. Carrington CB, Gaensler EA, Coutu RE, et al. Natural history and treated course of usual and desquamative interstitial pneumonia. N Engl J Med. 1978;298:801-809.
4. Cushley MJ, Davison AG, du Bois RM, et al. The Diagnosis, Assessment and Treatment of Diffuse Parenchymal Lung Disease in Adults. Thorax. 1999; 54: S1-S30.
5. Mapel DW, Samet JM, Coultas DB. Corticosteroids and the treatment of idiopathic pulmonary fibrosis. Past, present, and future. Chest. 1996; 110: 1058-1067.
6. Hubbard R, Johnston I, Britton J. Survival in patients with cryptogenic fibrosing alveolitis: a population-based cohort study. Chest. 1998; 113: 396-400.
7. Douglas WW, Ryu JH, Schroeder DR. Idiopathic pulmonary fibrosis: Impact of oxygen and colchicine, prednisone, or no therapy on survival. Am J Respir Crit Care Med. 2000; 161:1172-1178.
8. Nagai S, Kitaichi M, Hamada K, et al. Hospital-based historical cohort study of 234 histologically proven Japanese patients with IPF. Sarcoidosis Vasc Diffuse Lung Dis. 1999; 16:209-214.
9. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med. 2000,161:646-664.
10. Demedts M, Behr J, Buhl R, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med. 2005; 353: 2229-2242.
11. Dines DE. Pulmonary disease of vascular origin. Dis Chest. 1968; 54: 3-12.
12. Rossi GA, Bitterman PB, Rennard SI, et al. Evidence for chronic inflammation as a component of the interstitial lung disease associated with progressive systemic sclerosis. Am Rev Respir Dis. 1985; 131:612-617.
13. Helfrich DJ, Banner B, Steen VD, Medsger TA, Jr. Normotensive renal failure in systemic sclerosis. Arthritis Rheum. 1989; 32: 1128-1134.
14. Scorza R, Rivolta R, Mascagni B, et al. Effect of iloprost infusion on the resistance index of renal vessels of patients with systemic sclerosis. J Rheumatol. 1997;24:1944-1948.
15. Akesson A, Scheja A, Lundin A, Wollheim FA. Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide. Arthritis Rheum. 1994; 37: 729-735.
16. Davas EM, Peppas C, Maragou M, et al. Intravenous cyclophosphamide pulse therapy for the treatment of lung disease associated with scleroderma. Clin Rheumatol. 1999; 18: 455-461.
17. Silver RM, Warrick JH, Kinsella MB, et al. Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. J Rheumatol. 1993; 20: 838-844.
18. Varai G, Earle L, Jimenez SA, et al. A pilot study of intermittent intravenous cyclophosphamide for the treatment of systemic sclerosis associated lung disease. J Rheumatol. 1998; 25:1325-1329.
19. White B, Moore WC, Wigley FM, et al. Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis. Ann Intern Med. 2000; 132: 947-954.
20. Steen VD, Lanz JK, Jr., Conte C, et al. Therapy for severe interstitial lung disease in systemic sclerosis. A retrospective study. Arthritis Rheum. 1994;37:1290-1296.
21. Pakas I, loannidis JP, Malagari K, et al. Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease. J Rheumatol. 2002; 29: 298-304.
22. Giacomelli R, Valentini G, Salsano F, et al. Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis. J Rheumatol. 2002;29:731-736.
23. Griffiths B, Miles S, Moss H, et al. Systemic sclerosis and interstitial lung disease: a pilot study using pulse intravenous methylprednisolone and cyclophosphamide to assess the effect on high resolution computed tomography scan and lung function. J Rheumatol. 2002; 29: 2371-2378.
24. Hoyles RK, Ellis RW, Wellsbury J, et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum. 2006; 54: 3962-3970.
25. Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006; 354: 2655-2666.